ArticleClinical rheumatology2026
Baseline pain severity is associated with short-term pain reduction after intramuscular glucocorticoids; other clinical characteristics are not associated: a prospective cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIntramuscular (i.m.) glucocorticoids (GCs) are commonly prescribed in inflammatory arthritis (IA) and osteoarthritis (OA), yet prospective evidence on factors associated with treatment response remains limited. This study examined the association between baseline clinical characteristics and short-term (2 weeks) pain change following i.m. GC injections in IA and OA patients.
methodOur prospective cohort study (Sint Maartenskliniek, Nijmegen) included IA and OA patients receiving an i.m. GC injection between March and June 2024. Numeric Rating Scale (NRS) pain scores were assessed at baseline and at 2, 4, 6, and 12 weeks post-injection. The primary outcome was change in NRS pain at 2 weeks. Associations between baseline characteristics and treatment response measured by NRS pain change were analyzed using univariable and multivariable linear regression.
resultsOf 299 patients, 240 had available 2-week follow-up data. The median baseline NRS pain was 7 (95% CI, 6.7-7.3), decreasing to 4 (95% CI, 3.7-4.3) at 2 weeks (mean change, - 2.1; 95% CI, - 2.5 to - 1.7). Baseline NRS pain was the only significant predictor of response (β = - 0.516, p < 0.001).
conclusioni.m. GCs administration was followed by a clinically relevant pain reduction in patients with IA and OA. Higher baseline NRS pain is the only factor associated with short-term pain change, whereas other baseline characteristics show no association. These findings suggest that commonly available clinical variables have limited value in explaining variation in short-term treatment response after i.m. GC injections. Key Points • Baseline NRS pain is the only factor associated with two-week pain improvement after intramuscular glucocorticoids • Other routinely collected clinical characteristics are not significantly associated with treatment response.
Indexed as
Identifiers
42467348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.